Chemocentryx Financial Statements From 2010 to 2021

CCXI -  USA Stock  

USD 15.78  0.20  1.25%

Chemocentryx financial statements provide useful quarterly and yearly information to potential Chemocentryx investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Chemocentryx financial statements helps investors assess Chemocentryx's valuation, profitability, and current liquidity needs.
We have found ninety-nine available fundamental signals for Chemocentryx, which can be analyzed and compared to other ratios and to its rivals. Please verify all of Chemocentryx prevailing fundamental drivers against the trend between 2010 and 2021 to make sure the company can sustain itself down the road.
Chemocentryx Enterprise Value is most likely to increase significantly in the upcoming years. The preceding year's Enterprise Value was reported at 4.29 Billion. The current Invested Capital is estimated to increase to about 537.4 M, while Net Income Per Employee is projected to decrease to (447.8 K).

Search Financial Statements 

 
Refresh
Check Chemocentryx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Chemocentryx main balance sheet or income statement drivers, such as Gross Profit of 54.5 M, Interest Expense of 2.9 M or Operating Expenses of 98.9 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0482, PPandE Turnover of 4.86 or Receivables Turnover of 446. Chemocentryx financial statements analysis is a perfect complement when working with Chemocentryx Valuation or Volatility modules. It can also supplement various Chemocentryx Technical models. Continue to the analysis of Chemocentryx Correlation against competitors.

Chemocentryx Revenues

54.5 MillionShare

Chemocentryx Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets559.9 M518.9 M207.2 M
Increasing
Slightly volatile
Cash and Equivalents30.2 M32.3 M23.5 M
Increasing
Slightly volatile
Investments461.9 M428.1 M162.3 M
Increasing
Slightly volatile
Investments Current436.2 M404.3 M147.3 M
Increasing
Slightly volatile
Investments Non Current21.4 M23.8 M17.1 M
Increasing
Slightly volatile
Deferred Revenue54.5 M36.6 M69.3 M
Increasing
Slightly volatile
Property Plant and Equipment Net56.2 M52.1 M10.4 M
Increasing
Slightly volatile
Trade and Non Trade Receivables173.4 K169 K13.2 M
Decreasing
Very volatile
Trade and Non Trade Payables13.9 M12.9 MM
Increasing
Slightly volatile
Total Liabilities109.2 M133.3 M70.8 M
Increasing
Slightly volatile
Shareholders Equity416.1 M385.6 M133.4 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income123 K114 K14.3 K
Increasing
Stable
Current Assets476.4 M441.6 M181.1 M
Increasing
Slightly volatile
Assets Non Current83.4 M77.3 M26.1 M
Increasing
Slightly volatile
Current Liabilities42.9 M51.6 M28.5 M
Increasing
Slightly volatile
Liabilities Non Current66.3 M81.7 M42.3 M
Increasing
Slightly volatile
Total Debt68.1 M63.1 M17 M
Increasing
Slightly volatile
Debt Current7.8 M7.2 M4.5 M
Increasing
Slightly volatile
Debt Non Current61.3 M56.8 M15.8 M
Increasing
Slightly volatile
Shareholders Equity USD416.1 M385.6 M133.4 M
Increasing
Slightly volatile
Cash and Equivalents USD30.2 M32.3 M23.5 M
Increasing
Slightly volatile
Total Debt USD68.1 M63.1 M17 M
Increasing
Slightly volatile
Accounts Payable13.9 M12.9 MM
Increasing
Slightly volatile
Receivables140.6 K137 K22.1 M
Decreasing
Slightly volatile

Chemocentryx Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues54.5 M64.9 M32.9 M
Increasing
Slightly volatile
Selling General and Administrative Expense45.5 M42.2 M19 M
Increasing
Slightly volatile
Research and Development Expense67.1 M77.9 M46.9 M
Increasing
Slightly volatile
Operating Expenses98.9 M120.1 M64.8 M
Increasing
Slightly volatile
Interest Expense2.9 M2.6 M881 K
Increasing
Slightly volatile
Consolidated Income(56.8 M)(55.4 M)(34 M)
Decreasing
Slightly volatile
Net Income(56.8 M)(55.4 M)(34 M)
Decreasing
Slightly volatile
Net Income Common Stock(56.8 M)(55.4 M)(34 M)
Decreasing
Slightly volatile
Weighted Average Shares57.7 M65.7 M41.4 M
Increasing
Slightly volatile
Weighted Average Shares Diluted57.7 M65.7 M41.5 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(54.1 M)(52.7 M)(33.2 M)
Decreasing
Slightly volatile
Revenues USD54.5 M64.9 M32.9 M
Increasing
Slightly volatile
Net Income Common Stock USD(56.8 M)(55.4 M)(34 M)
Decreasing
Slightly volatile
Earning Before Interest and Taxes USD(54.1 M)(52.7 M)(33.2 M)
Decreasing
Slightly volatile
Gross Profit54.5 M64.9 M32.9 M
Increasing
Slightly volatile
Operating Income(56.6 M)(55.2 M)(34.9 M)
Decreasing
Slightly volatile

Chemocentryx Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals(274 M)(267 M)(55.5 M)
Decreasing
Slightly volatile
Net Cash Flow from Financing384.8 M356.6 M84.8 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 5.1 MM4.4 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares384.1 M356 M82.5 M
Increasing
Slightly volatile
Net Cash Flow from Investing(289.8 M)(282.4 M)(58.6 M)
Decreasing
Slightly volatile
Net Cash Flow from Operations(83.3 M)(81.1 M)(24.3 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(7.1 M)(6.9 M)436.5 K
Increasing
Very volatile
Share Based Compensation24.7 M22.9 M10.1 M
Increasing
Slightly volatile
Depreciation Amortization and AccretionM2.8 MM
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share(0.91)(0.84)(0.8396)
Increasing
Stable
Earnings per Diluted Share(0.91)(0.84)(0.8404)
Increasing
Stable
Earnings per Basic Share USD(0.91)(0.84)(0.8396)
Increasing
Stable
Return on Average Equity(0.19)(0.174)(0.402)
Decreasing
Stable
Return on Average Assets(0.13)(0.124)(0.2009)
Increasing
Very volatile
Return on Invested Capital(0.18)(0.163)(0.2704)
Decreasing
Very volatile
Gross Margin0.890.90.9829
Decreasing
Slightly volatile
Profit Margin(0.92)(0.853)(2.3336)
Increasing
Stable
EBITDA Margin(0.83)(0.77)(2.2637)
Increasing
Stable
Return on Sales(0.87)(0.812)(2.3038)
Increasing
Stable
Asset Turnover0.170.1450.1892
Decreasing
Very volatile
Enterprise Value over EBITDA(88.11)(85.852)(23.0043)
Decreasing
Slightly volatile
Enterprise Value over EBIT(83.13)(81.0)(22.0943)
Decreasing
Slightly volatile
Price to Earnings Ratio(75.65)(73.714)(20.4639)
Decreasing
Slightly volatile
Sales per Share1.490.9881.9013
Decreasing
Slightly volatile
Price to Sales Ratio56.1962.68144.7688
Decreasing
Stable
Price to Book Value12.7411.11310.5893
Increasing
Slightly volatile
Debt to Equity Ratio0.360.3461.5622
Increasing
Stable
Current Ratio8.048.5658.3682
Decreasing
Slightly volatile
Free Cash Flow per Share(1.51)(1.47)(0.1165)
Decreasing
Slightly volatile
Book Value per Share5.35.875.2519
Decreasing
Slightly volatile
Tangible Assets Book Value per Share7.317.8997.4712
Decreasing
Slightly volatile
Total Assets Per Share8.157.47137.3611
Decreasing
Slightly volatile
Cash Flow Per Share(1.2)(1.1683)(0.0714)
Decreasing
Slightly volatile
Return on Investment(24.01)(22.2578)(39.1133)
Decreasing
Stable
Operating Margin(100)(97.78)(23.9841)
Decreasing
Slightly volatile
Receivables Turnover44641475.8209
Increasing
Slightly volatile
PPandE Turnover4.864.738518.4129
Increasing
Very volatile
Cash and Equivalents Turnover1.531.81081.3257
Increasing
Stable
Accounts Payable Turnover9.228.983626.0987
Decreasing
Very volatile
Accrued Expenses Turnover4.013.47443.4467
Increasing
Very volatile
Long Term Debt to Equity0.04820.04690.1777
Increasing
Stable
Quick Ratio9.098.47028.089
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets82.1375.161474.2574
Decreasing
Stable
Revenue to Assets0.180.12510.1775
Decreasing
Very volatile

Chemocentryx Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax(56.8 M)(55.4 M)(34 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(51.3 M)(49.9 M)(32.1 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD(51.3 M)(49.9 M)(32.1 M)
Decreasing
Slightly volatile
Market Capitalization4.6 B4.3 B1.2 B
Increasing
Slightly volatile
Enterprise Value4.6 B4.3 B1.2 B
Increasing
Slightly volatile
Invested Capital537.4 M498.1 M169.6 M
Increasing
Slightly volatile
Average Equity343 M317.9 M123.9 M
Increasing
Slightly volatile
Average Assets483.2 M447.8 M194.2 M
Increasing
Slightly volatile
Invested Capital Average349.3 M323.8 M136.1 M
Increasing
Slightly volatile
Tangible Asset Value559.9 M518.9 M207.2 M
Increasing
Slightly volatile
Free Cash Flow(99.1 M)(96.6 M)(27.3 M)
Decreasing
Slightly volatile
Working Capital420.8 M390 M151.5 M
Increasing
Slightly volatile
Revenue Per Employee450.8 K486.6 K416.4 K
Increasing
Stable
Net Income Per Employee(447.8 K)(415.1 K)(454.4 K)
Decreasing
Stable

Chemocentryx Fundamental Market Drivers

Forward Price Earnings-8.93
Average Daily Volume Last 10 Day1.18M
Average Daily Volume In Three Month2.43M
Fifty Day Average15.06
Two Hundred Day Average26.34

Chemocentryx Upcoming Events

Upcoming Quarterly Report8th of November 2021
Next Earnings Report7th of March 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

About Chemocentryx Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Chemocentryx income statement, its balance sheet, and the statement of cash flows. Chemocentryx investors use historical funamental indicators, such as Chemocentryx's revenue or net income, to determine how well the company is positioned to perform in the future. Although Chemocentryx investors may use each financial statement separately, they are all related. The changes in Chemocentryx's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Chemocentryx's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Chemocentryx Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Chemocentryx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Deferred Revenue36.6 M54.5 M
Revenues64.9 M54.5 M
Revenue to Assets 0.13  0.18 
Revenue Per Employee486.6 K450.8 K
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California. Chemocentryx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Chemocentryx without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now

   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Pair Trading with Chemocentryx

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemocentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemocentryx will appreciate offsetting losses from the drop in the long position's value.

Chemocentryx Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Chemocentryx and Dynavax Technologies. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Chemocentryx Correlation against competitors. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.